Cargando…

COVID‐19 in a patient with severe asthma treated with Omalizumab

Detalles Bibliográficos
Autores principales:	Lommatzsch, Marek, Stoll, Paul, Virchow, Johann Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323189/ https://www.ncbi.nlm.nih.gov/pubmed/32544254 http://dx.doi.org/10.1111/all.14456

Ejemplares similares

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

Asthma und Covid-19
por: Buhl, Roland, et al.
Publicado: (2020)

Against all odds: anti-IgE for intrinsic asthma?
por: Lommatzsch, Marek, et al.
Publicado: (2014)

Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control
por: de Carvalho-Pinto, Regina Maria, et al.
Publicado: (2017)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2018)

Adults with asthma treated with add-on omalizumab report less limitation in activities of daily living
por: de Oliveira, Joice Mara, et al.
Publicado: (2022)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Novel strategies for the treatment of asthma
por: Lommatzsch, Marek, et al.
Publicado: (2016)

Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland
por: Stelmach, Iwona, et al.
Publicado: (2015)

COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab()
por: Baldallo, Cinthia, et al.
Publicado: (2021)

Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia
por: Kupryś-Lipińska, Izabela, et al.
Publicado: (2015)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Stage-dependent association of BDNF and TGF-β(1) with lung function in stable COPD
por: Stoll, Paul, et al.
Publicado: (2012)

Imbalance of dendritic cell co-stimulation in COPD
por: Stoll, Paul, et al.
Publicado: (2015)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Metabolomics to identify omalizumab responders among children with severe asthma: A prospective study
por: Carraro, Silvia, et al.
Publicado: (2022)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

279 Near-Fatal Asthma Treated with Omalizumab
por: Contreras Contreras, Elvia Angelica, et al.
Publicado: (2012)

Efficacy of omalizumab in reducing latex allergy
por: Aruanno, Arianna, et al.
Publicado: (2021)

Benefits of omalizumab on anxiety and depression in patients with severe asthma
por: Uzer, Fatih, et al.
Publicado: (2018)

Appropriate selection for omalizumab treatment in patients with severe asthma?
por: Nygaard, Leo, et al.
Publicado: (2017)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

A review of omalizumab for the management of severe asthma
por: Lin, Ching-Hsiung, et al.
Publicado: (2016)

The Neurotrophins Nerve Growth Factor, Brain-derived Neurotrophic Factor, Neurotrophin-3, and Neurotrophin-4 Are Survival and Activation Factors for Eosinophils in Patients with Allergic Bronchial Asthma
por: Nassenstein, Christina, et al.
Publicado: (2003)

Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma
por: Prætorius, Katrine, et al.
Publicado: (2021)

Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases
por: Fiorino, Irene, et al.
Publicado: (2014)

Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD
por: Stoll, Paul, et al.
Publicado: (2014)

Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial
por: Lommatzsch, Marek, et al.
Publicado: (2013)

Age of asthma onset does not impact the response to omalizumab
por: Rogers, Linda, et al.
Publicado: (2023)

Omalizumab as a Provoking Factor for Venous Thromboembolism
por: Oblitas, Crhistian-Mario, et al.
Publicado: (2019)

282 Successful Treatment of Severe Nonallergic Asthma by Omalizumab. An Observation
por: Bergmann, Karl-Christian, et al.
Publicado: (2012)

Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab
por: de Brito, Marianne, et al.
Publicado: (2018)

Omalizumab as add‐on therapy in a patient with severe asthma and OSA
por: Scioscia, Giulia, et al.
Publicado: (2020)

A case of acute exacerbation of chronic spontaneous urticaria due to COVID-19 immediately after omalizumab administration
por: Hayama, Koremasa, et al.
Publicado: (2022)

Is Omalizumab a Problem-Solving Remedy in Severe Asthma?
por: Kim, Doh Hyung, et al.
Publicado: (2018)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Good outcomes of pregnancy in two cases of women treated with omalizumab due to the severe asthma
por: Kuprys-Lipinska, Izabela, et al.
Publicado: (2013)

Efficacy of Omalizumab in a Patient with Angioedema Clinically Resembling a Hereditary Angioedema
por: Kutlu, Ali, et al.
Publicado: (2016)

A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous Urticaria
por: Lefévre, Anna Cecilie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gmuvacili4egh1s0udeia83job